Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $208,050.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $73.00, for a total transaction of $208,050.00. Following the completion of the transaction, the chief financial officer directly owned 168,993 shares in the company, valued at approximately $12,336,489. The trade was a 1.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Trading Down 1.1%

NASDAQ:ANIP opened at $72.18 on Friday. The firm has a market capitalization of $1.66 billion, a P/E ratio of 15.56, a P/E/G ratio of 2.35 and a beta of 0.50. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The company has a fifty day moving average of $75.19 and a 200 day moving average of $78.09. ANI Pharmaceuticals, Inc. has a 52 week low of $69.58 and a 52 week high of $97.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same quarter last year, the firm earned $1.80 EPS. The company’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Analyst Ratings Changes

ANIP has been the topic of a number of research analyst reports. Canaccord Genuity Group reduced their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective for the company. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Guggenheim reduced their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Finally, Oppenheimer initiated coverage on ANI Pharmaceuticals in a report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 target price for the company. Three analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $98.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership raised its holdings in ANI Pharmaceuticals by 19.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after purchasing an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after buying an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $28,406,000. Deutsche Bank AG bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $26,775,000. Finally, William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth about $21,372,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.

ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.